HI
ADPT icon

Hudock Inc’s Adaptive Biotechnologies ADPT Stock Holding History

Hudock Inc’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-900
Closed -$36K – 802
2021
Q1 		$36K Hold
900
– – 0.01% 357
2020
Q4 		$53K Hold
900
– – 0.02% 292
2020
Q3 		$43K Hold
900
– – 0.02% 290
2020
Q2 		$43K Hold
900
– – 0.02% 282
2020
Q1 		$25K Hold
900
– – 0.01% 300
2019
Q4 		$26K Hold
900
– – 0.01% 308
2019
Q3 		$27K Sell
900
-400
-31% -$16.3K 0.01% 308
2019
Q2 		$62K Buy
+1,300
New +$57.6K 0.02% 220

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hudock Inc's ADPT Position: Q2 2021 in Review

Hudock Inc sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 900 shares — an estimated $36K sold.

Hudock Inc first reported a position in ADPT in Q2 2019 and held it in 8 quarters. The position peaked at $62K in Q2 2019. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Hudock Inc reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Hudock Inc sold 900 Adaptive Biotechnologies shares in Q2 2021, an estimated $36K.
  • Hudock Inc first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 8 quarters.
  • Hudock Inc's Adaptive Biotechnologies position peaked at $62K in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Hudock Inc's 13F filing for Q2 2021, filed 9 Aug 2021.